학술논문
Evaluation of serum and urine biomarkers for severe COVID-19.
Document Type
Academic Journal
Author
Shansky YD; Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia.; Yanushevich OO; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Gospodarik AV; Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia.; Maev IV; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Krikheli NI; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Levchenko OV; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Zaborovsky AV; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Evdokimov VV; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Solodov AA; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Bely PA; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Andreev DN; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Serkina AN; Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia.; Esiev SS; Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia.; Department of Expertise in Doping and Drug Control, Mendeleev University of Chemical Technology of Russia, Moscow, Russia.; Komarova AV; Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia.; Department of Expertise in Doping and Drug Control, Mendeleev University of Chemical Technology of Russia, Moscow, Russia.; Sokolov PS; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Fomenko AK; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Devkota MK; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Tsaregorodtsev SV; Federal State Budgetary Educational Institution of Higher Education 'Russian University of Medicine' of the Ministry of Health of the Russian Federation, Moscow, Russia.; Bespyatykh JA; Laboratory of Molecular Medicine, Center of Molecular Medicine and Diagnostics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia.; Department of Expertise in Doping and Drug Control, Mendeleev University of Chemical Technology of Russia, Moscow, Russia.
Source
Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2296-858X
Abstract
Introduction: The new coronavirus disease, COVID-19, poses complex challenges exacerbated by several factors, with respiratory tissue lesions being notably significant among them. Consequently, there is a pressing need to identify informative biological markers that can indicate the severity of the disease. Several studies have highlighted the involvement of proteins such as APOA1, XPNPEP2, ORP150, CUBN, HCII, and CREB3L3 in these respiratory tissue lesions. However, there is a lack of information regarding antibodies to these proteins in the human body, which could potentially serve as valuable diagnostic markers for COVID-19. Simultaneously, it is relevant to select biological fluids that can be obtained without invasive procedures. Urine is one such fluid, but its effect on clinical laboratory analysis is not yet fully understood due to lack of study on its composition.
Methods: Methods used in this study are as follows: total serum protein analysis; ELISA on moderate and severe COVID-19 patients' serum and urine; bioinformatic methods: ROC analysis, PCA, SVM.
Results and Discussion: The levels of antiAPOA1, antiXPNPEP2, antiORP150, antiCUBN, antiHCII, and antiCREB3L3 exhibit gradual fluctuations ranging from moderate to severe in both the serum and urine of COVID-19 patients. However, the diagnostic value of individual anti-protein antibodies is low, in both blood serum and urine. On the contrary, joint detection of these antibodies in patients' serum significantly increases the diagnostic value as demonstrated by the results of principal component analysis (PCA) and support vector machine (SVM). The non-linear regression model achieved an accuracy of 0.833. Furthermore, PCA aided in identifying serum protein markers that have the greatest impact on patient group discrimination. The study revealed that serum serves as a superior analyte for describing protein quantification due to its consistent composition and lack of organic salts and drug residues, which can otherwise affect protein stability.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Shansky, Yanushevich, Gospodarik, Maev, Krikheli, Levchenko, Zaborovsky, Evdokimov, Solodov, Bely, Andreev, Serkina, Esiev, Komarova, Sokolov, Fomenko, Devkota, Tsaregorodtsev and Bespyatykh.)
Methods: Methods used in this study are as follows: total serum protein analysis; ELISA on moderate and severe COVID-19 patients' serum and urine; bioinformatic methods: ROC analysis, PCA, SVM.
Results and Discussion: The levels of antiAPOA1, antiXPNPEP2, antiORP150, antiCUBN, antiHCII, and antiCREB3L3 exhibit gradual fluctuations ranging from moderate to severe in both the serum and urine of COVID-19 patients. However, the diagnostic value of individual anti-protein antibodies is low, in both blood serum and urine. On the contrary, joint detection of these antibodies in patients' serum significantly increases the diagnostic value as demonstrated by the results of principal component analysis (PCA) and support vector machine (SVM). The non-linear regression model achieved an accuracy of 0.833. Furthermore, PCA aided in identifying serum protein markers that have the greatest impact on patient group discrimination. The study revealed that serum serves as a superior analyte for describing protein quantification due to its consistent composition and lack of organic salts and drug residues, which can otherwise affect protein stability.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Shansky, Yanushevich, Gospodarik, Maev, Krikheli, Levchenko, Zaborovsky, Evdokimov, Solodov, Bely, Andreev, Serkina, Esiev, Komarova, Sokolov, Fomenko, Devkota, Tsaregorodtsev and Bespyatykh.)